Iomeprol

Iomeprol
Clinical data
Trade names	Iomervu, others
License data	US DailyMed: Iomeprol;
Routes of; administration	Intravenous, intra-arterial
ATC code	V08AB10 (WHO) ;
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Metabolism	none
Elimination half-life	109±20 min
Excretion	Kidney
Identifiers
	IUPAC name 1-N,3-N-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-methylacetamido)-2,4,6-triiodobenzene-1,3-dicarboxamide;
CAS Number	78649-41-9;
PubChem CID	3731;
DrugBank	DB11705;
ChemSpider	3600;
UNII	17E17JBP8L;
KEGG	D01719;
ChEBI	CHEBI:31710;
CompTox Dashboard (EPA)	DTXSID1049061 ;
Chemical and physical data
Formula	C17H22I3N3O8
Molar mass	777.089 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Ic1c(c(I)c(c(I)c1N(C(=O)CO)C)C(=O)NCC(O)CO)C(=O)NCC(O)CO;
	InChI InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31); Key:NJKDOADNQSYQEV-UHFFFAOYSA-N;

Iomeprol, sold under the brand name Imeron among others, is a medication used as a radiocontrast agent in X-ray imaging.¹²³

Iomeprol was approved for medical use in the United States in November 2024.¹⁴⁵

Side effects

It is classified as a water-soluble, nephrotrophic, low osmolar X-ray contrast medium.² Low osmolar non-ionic agents are better tolerated and less likely to cause side effects than the high osmolar ionic agents.²

Society and culture

Iomeprol is not metabolized in the human body but excreted in unchanged form. It is decomposed slowly and can therefore accumulate in the environment.⁶

Legal status

Iomeprol was approved for medical use in the United States in November 2024.¹⁴

Brand names

Iomeprol is sold under the brand name Iomervu.¹

References

fda.gov
Rossiter D (2014). South African medicines formulary (11th ed.). Rondebosch, South Africa: Health and Medical Pub. Group .of the South African Medical Association. ISBN 978-1-875098-30-9. OCLC 869772940.
Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Iomeron 300 mg J/ml-Infusionsflasche.
"Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.
New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.
Pfundstein P, Martin C, Schulz W, Seitz W, Ruth KM, Wille A, et al. (January 2015). "IC-ICP/MS-Analytik". GIT Labor-Fachzeitschrift (in German): 29–31.

[Iomervu_FDA_label-1] .gov

[Rossiter_2014-2] Rossiter D (2014). South African medicines formulary (11th ed.). Rondebosch, South Africa: Health and Medical Pub. Group .of the South African Medical Association. ISBN 978-1-875098-30-9. OCLC 869772940.

[AC-3] Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Iomeron 300 mg J/ml-Infusionsflasche.

[Novel_Drug_Approvals_for_2024-4] "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.

[5] New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.

[6] Pfundstein P, Martin C, Schulz W, Seitz W, Ruth KM, Wille A, et al. (January 2015). "IC-ICP/MS-Analytik". GIT Labor-Fachzeitschrift (in German): 29–31.

1

2

3

4

5

6